MARKET

CBAY

CBAY

Cymabay Therapeu
NASDAQ
9.30
+0.32
+3.56%
After Hours: 9.39 +0.09 +0.98% 19:47 06/01 EDT
OPEN
8.98
PREV CLOSE
8.98
HIGH
9.44
LOW
8.89
VOLUME
1.16M
TURNOVER
0
52 WEEK HIGH
11.22
52 WEEK LOW
1.810
MARKET CAP
906.87M
P/E (TTM)
-7.8501
1D
5D
1M
3M
1Y
5Y
Cymabay Therapeu: Initial statement of beneficial ownership of securities
Press release · 05/22 21:31
Cymabay Therapeu: Statement of changes in beneficial ownership of securities
Press release · 05/22 21:30
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
Benzinga · 05/22 20:20
Cymabay Therapeu: Report of proposed sale of securities
Press release · 05/21 03:03
Why CymaBay Therapeutics Stock Nose-Dived This Week
Motley Fool · 05/19 21:59
LifeSci Capital Reaffirms Their Buy Rating on CymaBay Therapeutics (CBAY)
TipRanks · 05/17 00:55
SVB Securities Sticks to Their Buy Rating for CymaBay Therapeutics (CBAY)
TipRanks · 05/17 00:35
HC Wainwright & Co. Reiterates Cymabay Therapeutics (CBAY) Buy Recommendation
NASDAQ · 05/16 19:52
More
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. It is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. Its other product candidate, MBX-2982, targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.